Designing the next-generation clinical care pathway for Alzheimer’s disease
Résumé
The reconceptualization of Alzheimer’s disease (AD) as a clinical and biological construct has facilitated the development of
biomarker-guided, pathway-based targeted therapies, many of which have reached late-stage development with the near-term
potential to enter global clinical practice. These medical advances mark an unprecedented paradigm shift and requires an optimized
global framework for clinical care pathways for AD. In this Perspective, we describe the blueprint for transitioning from
the current, clinical symptom-focused and inherently late-stage diagnosis and management of AD to the next-generation pathway
that incorporates biomarker-guided and digitally facilitated decision-making algorithms for risk stratification, early detection,
timely diagnosis, and preventative or therapeutic interventions. We address critical and high-priority challenges, propose
evidence-based strategic solutions, and emphasize that the perspectives of affected individuals and care partners need to be
considered and integrated.
Domaines
Sciences du Vivant [q-bio]
Fichier principal
NATURE AGING_Next-generation AD patient journey_2022.pdf (1.29 Mo)
Télécharger le fichier
Origine : Publication financée par une institution